SECsense Logo

Lipella Pharmaceuticals Inc. 8-K Filing: Key Updates & Insights for Investors

$LIPO
Form 8-K
Filed on: 2024-12-30
Source
Lipella Pharmaceuticals Inc. 8-K Filing: Key Updates & Insights for Investors

Based on the provided section of the financial report, here are the key pieces of information and insights:

  1. Entity Information:
  • Company Name: Lipella Pharmaceuticals Inc.
  • CIK: 0001347242
  • SEC File Number: 005-93847
  • EIN: 20-2388040
  • Address: 7800 Susquehanna St., Suite 505, Pittsburgh, PA 15208
  • Contact Number: (412) 901-0315
  1. Report Type:
  • Filing Type: 8-K, which is used to report major events that shareholders should know about.
  1. Report Date:
  • Filing Date: December 30, 2024.
  1. Stock Information:
  • Common Stock: Par value of $0.0001 per share.
  • Trading Symbol: LIPO (listed on NASDAQ).
  1. Financial Measurements:
  • The report uses the currency unit of USD (U.S. Dollars) and shares for measurement purposes.
  • There is a note indicating a ratio of USD to shares, but specific values are not provided in the excerpt.
  1. Context and Metadata:
  • The context indicates a specific date reference (As of December 30, 2024), suggesting that the report reflects the company's status as of this date.
  1. XBRL Information:
  • The document follows the XBRL (eXtensible Business Reporting Language) format, which allows for enhanced data sharing and reporting.

Insights:

  • The filing is recent and likely contains important updates regarding corporate actions, financial performance, or other significant events for Lipella Pharmaceuticals.
  • The company operates in the pharmaceutical sector, which can have implications for regulatory scrutiny and market volatility.
  • The low par value of the common stock suggests a startup or growth stage company, which may be seeking to raise capital or expand operations.
  • Given that it is a Form 8-K, stakeholders should consider monitoring this filing closely for any potential impact on the stock price or future operations of Lipella Pharmaceuticals.

Overall, this report is critical for investors and stakeholders to understand current developments in Lipella Pharmaceuticals Inc. and assess its financial health and market position.